Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Biomarck completes enrolment in Phase II trial of NSCLC drug

Non-small cell lung cancer in a 54-year-old woman. Credit: Oregon State University.



  • Biomarck Pharmaceuticals

Go Top